References
- Lindblad P. Epidemiology of renal cell carcinoma. Scand. J. Surg.93(2), 88–96 (2004).
- Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA281(17), 1628–1631 (1999).
- Bos SD, Mellema CT, Mensink HJ. Increase in incidental renal cell carcinoma in the northern part of The Netherlands. Eur. Urol.37(3), 267–270 (2000).
- Mevorach RA, Segal AJ, Tersegno ME, Frank IN. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology39(6), 519–522 (1992).
- Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J. Urol.167(1), 57–60 (2002).
- Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol.166(5), 1611–1623 (2001).
- Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer88(3), 348–353 (2003).
- Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol.27(5), 612–624 (2003).
- Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer. J. Clin.54(1), 8–29 (2004).
- Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163(2), 408–417 (2003).
- Oudard S, George D, Medioni J et al. Treatment options in renal cell carcinoma: past, present and future. Ann. Oncol.18(Suppl. 10), 25–31 (2007).
- Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer. Res.10(Suppl.), 6342–6346 (2004).
- Hutson TE. Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence. The Oncologist16(Suppl. 2), 14–22 (2011).
- Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer115(1), 61–67 (2009).
- Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
- Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol.77(1), 48–62 (2011).
- Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol.22(8), 1812–1823 (2011).
- Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in RCC. Onkologie30, 519–524 (2007).
- Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch. Arztebl. Int.105(13), 232–237 (2008).
- Procopio G,Verzoni E, Guadalupi V et al. Sequential use of sorafenib (So) followed by sunitinib (Su) in metastatic renal cell cancer (mRCC): a single-institution experience [abstract]. Presented at: Genitourinary Cancers Symposium. Orlando, FL, USA, 26–28 February 2009 (Abstract 319).
- Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
- Silverman SL. From randomized controlled trials to observational studies. Am. J. Med.122(2), 114–120 (2009).
- Porta C, Paglino C, Cartenì G et al. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. EJCMO (2011) (In Press).
- Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol.54(6), 1373–1378 (2008).
- Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol.182, 29–34 (2009).
- Zimmerman K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear cell renal-cell carcinoma after progression on sorafenib. Oncology76(5), 350–354 (2009).
- Garcia JA, Hutson TE, Elson P et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer116(23), 5383–5390 (2010).
Websites
- NCCN Clinical Practice Guidelines in Oncology™Kidney Cancer. Version 2.2010. ©2009 National Comprehensive Cancer Network, Inc www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (Accessed 20 March 2011)
- ClinicalTrials.gov. NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-Alfa in Advanced Renal Cell Carcinoma Subjects (INTORACT) www.clinicaltrials.gov/ct2/show/NCT00631371?term=NCT00631371&rank=1 (Accessed 22 March 2011)
- ClinicalTrials.gov. NCT00378703. Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer www.clinicaltrials.gov/ct2/show/NCT00378703?term=NCT00378703&rank=1 (Accessed 22 March 2011)
- ClinicalTrials.gov. NCT00619268. Combination of Temsirolimus and Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (TORAVA) www.clinicaltrials.gov/ct2/show/NCT00619268?term=NCT00619268&rank=1 (Accessed 22 March 2011)
- ClinicalTrials.gov. NCT00719264. Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer www.clinicaltrials.gov/ct2/show/NCT00719264?term=NCT00719264&rank=1 (Accessed 22 March 2011)
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. V. 2.2010 www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (Accessed 22 March 2011)
- Ljungberg B, Cowan N, Hanbury DC et al. European Association of Urology Guidelines on Renal Cell Carcinoma (2010) www.uroweb.org/gls/pdf/Renal%20Cell%20Carcinoma%202010.pdf (Accessed 22 March 2011)
- ClinicalTrials.gov. NCT00732914. A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced/Metastatic Renal Cell Carcinoma http://clinicaltrials.gov/ct2/show/NCT00732914 (Accessed 22 March 2011)
- Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed 22 March 2011)
- ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00930033 (Accessed 25 August 2011)
- EORTC protocol 30073 – SURTIME www.eortc.be/protoc/details.asp?protocol=30073 (Accessed 25 August 2011)